BioSpecifics Technologies Corp. is a profitable, biopharmaceutical company that is the originator of collagenase-based therapies with injectable collagenase (CCH) being developed for multiple indications. CCH is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Canada, Europe and Australia.

In addition to Dupuytren's contracture and Peyronie's disease, Endo is managing the research and development of CCH for their six licensed clinical-stage indications, which include adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis and human and canine lipomas. BioSpecifics is currently managing the development of CCH for uterine fibroids and announced positive results from the Phase 1 clinical trial in March 2019 at the 66th Annual Meeting for the Society for Reproductive Investigation with additional data from the Phase 1 trial expected to be presented at an upcoming medical meeting in the second half of 2019. BioSpecifics also initiates the development of CCH in new potential indications. Endo has the right to opt-in to new indications.